Researchers Engineered Enzyme to Reverse Cell Senescence
The synthetic kinase expands NADP(H) pools, restoring metabolic function and proliferation in human primary cells.
Updated on Oct. 14, 2026 in Life Sciences
Researchers have developed a synthetic Staphylococcus aureus NAD kinase (SaNADK) capable of expanding mammalian NADP(H) pools to counteract cellular senescence. This research-stage development restored metabolic health and proliferative capacity in human primary fibroblasts.
Why it matters
This mechanism offers a new approach to addressing age-associated metabolic decline by specifically targeting the depletion of essential cellular cofactors. It provides a deeper understanding of how redox coupling maintains cellular function during the aging process.
The study utilized a constitutively active Staphylococcus aureus NAD kinase to increase NADP(H) levels, successfully rescuing de novo pyrimidine biosynthesis and reductive carboxylation in cells suffering from mitochondrial inhibition.
The players
Nature Metabolism
A peer-reviewed scientific journal that focuses on the physiological and molecular mechanisms of metabolism.
The details
Researchers modeled redox coupling using Escherichia coli soluble transhydrogenase (EcSTH) to induce NADH-reductive stress and NADPH depletion in primary human fibroblasts. While normalizing the NADH/NAD ratio alone failed to rescue these cells, the introduction of the SaNADK enzyme corrected the underlying metabolic dysregulation. This process specifically enables primary cells, which are heavily reliant on NADPH-driven reductive carboxylation, to overcome proliferation arrest and phenotypic features of aging.
Timeline
October 14, 2026: Research article published in Nature Metabolism.
The Tech Race
While the broader field has long centered on NAD+ precursor supplementation to combat aging, this work identifies the NADP(H) pool as a critical bottleneck for cellular viability. It challenges the sufficiency of NAD+ restoration alone, proposing a targeted enzymatic intervention for metabolic renewal.
This development remains at the experimental stage and is currently limited to laboratory research using human primary cells and rodent models. There are no clinical applications or consumer products available, and the safety of this enzymatic intervention in humans is currently unknown.
The takeaway
This finding demonstrates that restoring specific enzymatic pathways can reverse signs of cellular aging that were previously thought to be permanent. Watch for follow-up studies investigating whether this synthetic kinase approach can maintain metabolic function in long-term in vivo models.
Further reading
For broader context on current approaches to metabolic engineering, visit the Life Sciences section.
More information
View the original research in the Nature Metabolism research article.
Source note: This article includes information reported by Nature.
